Pain

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Monday, August 8, 2022 - 9:01pm
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Clinical Trials, U.S. Securities and Exchange Commission, Salesforce, CFDA, GLP, Late, Drug, Clinical trial, Trial of the century, Ocular hypertension, Security (finance), Research, Pain, Marketing, Patient, International, CMS, MD, Allergic conjunctivitis, Pharmacovigilance, Part, AAO, Inflammation, Annual general meeting, 3D ultrasound, Duane syndrome, AMD, Safety, Nature, Webcast, Physician, Software, Intraocular pressure, ID, Interim, Dexamethasone, Growth, ASC, OPPS, Therapy, COVID-19, Axitinib, Association for Research in Vision and Ophthalmology, Investor, PMDA, Advertising, FDA, Association, Placebo, Private Securities Litigation Reform Act, Eye, Review, Company, Depreciation, NASDAQ, ARVO, EMA, Pharmaceutical industry, Medical device, Video game, Renewable energy, Health insurance, Ophthalmology, Retina

Net product revenue of DEXTENZA for the quarter was $12.1 million, a 9% increase over the second quarter of 2021.

Key Points: 
  • Net product revenue of DEXTENZA for the quarter was $12.1 million, a 9% increase over the second quarter of 2021.
  • Net product revenue of DEXTENZA in the second quarter of 2022 was $12.1 million versus $11.1 million in the comparable quarter of 2021, reflecting a 9% increase.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $4.8 million in the second quarter of 2022 versus $4.9 million for the comparable quarter of 2021.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Win Free Gas for a Year with Carvana’s Gassed Up Giveaway Sweepstakes!

Retrieved on: 
Monday, August 8, 2022 - 4:54pm
Internet, Automotive, Specialty, Other Automotive, Technology, Online Retail, General Automotive, Retail, Online, Multimedia, NYSE, Shell, Technology, YouTube, Sale, VOID, Machine, LLC, Hope, Pain, Blog, Instagram, DOES, Twitter, Fortune: Million Pound Giveaway, Online chat, Drawing, Heart, Online shopping, Facebook, Carvana

Carvanas iconic state-of-the-art steel and glass structures offer car buyers all across the U.S. a one-of-a-kind, immersive tech-forward experience, powered by the companys resounding Well Drive You Happy mantra.

Key Points: 
  • Carvanas iconic state-of-the-art steel and glass structures offer car buyers all across the U.S. a one-of-a-kind, immersive tech-forward experience, powered by the companys resounding Well Drive You Happy mantra.
  • Customers can also sell their current vehicle to Carvana and receive a real offer just as quickly, without even purchasing a vehicle.
  • Every customer that selects Car Vending Machine pickup at any location across the U.S. will automatically be entered into the drawing to win a years worth of free gas.
  • Founded in 2012 and based in Phoenix, Carvanas (NYSE: CVNA) mission is to change the way people buy and sell cars.

BC Dentists Dismayed by Absence of Dedicated Seat on New Oral Health College Board

Retrieved on: 
Monday, August 8, 2022 - 4:00pm
Risk, Dentist, Dentistry, Learning, Board, Dental care, Pain, Human, BCDA, Patient, Dental assistant, Ministry, List of health departments and ministries, Dental hygienist, BC, Health

VANCOUVER, BC, Aug. 8, 2022 /CNW/ -The BC Dental Association (BCDA) is shocked and appalled after learning that BC's new Oral Health Regulatory College has chosen to not provide dentists with a dedicated position on its Board, in its revised proposed bylaws .

Key Points: 
  • VANCOUVER, BC, Aug. 8, 2022 /CNW/ -The BC Dental Association (BCDA) is shocked and appalled after learning that BC's new Oral Health Regulatory College has chosen to not provide dentists with a dedicated position on its Board, in its revised proposed bylaws .
  • BC dentists disappointed new amalgamated oral health college has no dedicated Board position for their profession.
  • "Dentists are the only oral health professionals with hospital admitting privileges and are trained to deal with complex oral health conditions.
  • BCDA strongly urges the Oral Health Regulatory College and Ministry of Health to reconsider the proposed Board composition to reserve at least one dedicated position for a dentist registrant.

REGENATIVE LABS RELEASES NEW STUDY TO REVOLUTIONIZE TREATMENT FOR PATIENTS WITH DIABETIC FOOT ULCERS

Retrieved on: 
Monday, August 8, 2022 - 2:00pm
FDA, Multimedia, Amputation, Risk, Joint, Medicare, Regenerative medicine, Standard of care, USD, Hospital, Knowledge, Research, Pain, MDPI, AATB, Patient, DFU, Diabetes, Health, Debridement, Infection, Disease, Ligament, Physician, Time, Wharton, Ulcer, Labs, CHS, Pharmaceutical industry

PENSACOLA, Fla., Aug. 8, 2022 /PRNewswire/ -- A new MDPI study, co-authored by Regenative Labs signifies a huge win for patients suffering from diabetic foot ulcers (DFUs). DFUs are debilitating for an individual. They are painful, long lasting, and, even with proper care, can lead to amputation. The current standard of care for DFUs is debridement, the medical removal of dead, damaged, or infected tissue to improve the healing potential of the remaining healthy tissue. The increased healing time and augmented risk of amputation associated with the current standard of care only solidifies the need for new DFU treatment alternatives. Regenerative medicine is such an alternative.

Key Points: 
  • PENSACOLA, Fla., Aug. 8, 2022 /PRNewswire/ -- A new MDPI study, co-authored by Regenative Labs signifies a huge win for patients suffering from diabetic foot ulcers (DFUs).
  • We provide the highest quality amniotic membrane allograft to allow doctors to provide predictable outcomes for their patients," shared Regenative Labs CEO, Tyler Barrett.
  • Medicare now recognizes the medical necessity of amniotic membrane allografts in the treatment of both DFUs and venous stasis ulcers.
  • About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient's conditions using Wharton's Jelly innovations rather than masking the pain with other treatments.

SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

Retrieved on: 
Monday, August 8, 2022 - 1:55pm
U.S. Securities and Exchange Commission, Irritability, Status epilepticus, Tourette syndrome, GLOBE, Binary relation, Deviance (sociology), Population, Private Securities Litigation Reform Act, SEC, Clinical trial, THC, Ethics committee, Research, Communication, Pain, Annual report, Autism, Patient, Cannabinoid, Agitation, Company, Clinical Global Impression, Alzheimer's disease, Behavior, Central nervous system, Parent, Ministry, Safety, ASD, Risk, CBD, Intention, Cannabidiol, Nasdaq, TEL, Pharmaceutical industry

TEL AVIV, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has received approval from the Israeli Ministry of Health to conduct the Company’s clinical trial for SCI-210 in patients suffering from autism spectrum disorder ("ASD").

Key Points: 
  • Recently, the Company announced it received approval from the Ethics Committee of The Soroka University Medical Center, in Be'er-Sheva, Israel, to conduct the Companys clinical trial.
  • We are pleased to achieve another important milestone that brings us one step closer toward initiation of our clinical trial in ASD, commented Oz Adler, SciSparc's Chief Executive Officer.
  • "ASD symptoms in pediatric patients may cause a sever decrease in life quality, for parents and children.
  • The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

AvidXchange Offers a Complete Purchase to Pay Solution Purpose-Built for the Construction Industry

Retrieved on: 
Monday, August 8, 2022 - 2:00pm
U.S. Securities and Exchange Commission, Hand, Risk, AvidxChange Music Factory, Industry, GLOBE, Phrase, Technology, SEC, Sage Intacct, Security (finance), Construction, Annual report, Pain, Titanium, AP, Nature, Workflow, Private Securities Litigation Reform Act, Nasdaq, Time, Online shopping

This offering liberates construction professionals like contractors and developers from having to match purchase orders, manage invoices and facilitate payments by hand.

Key Points: 
  • This offering liberates construction professionals like contractors and developers from having to match purchase orders, manage invoices and facilitate payments by hand.
  • Instead, these finance tasks can be managed remotely and more efficiently from anywhere and at any time via one centralized, fully automated platform.
  • AvidXchange is a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses and their suppliers.
  • To learn more about how AvidXchange is transforming the way companies pay their bills, visit www.AvidXchange.com .

Devic's Syndrome Treatment Global Market Report 2022: Soliris (Eculizumab) to Fuel Considerable Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 12:38pm
Health, Other Health, Death, Antibody, Woman, Alexion, Neuromyelitis optica spectrum disorder, Autoantibody, C5a, Inflammation, CNS, Degenerative disease, DST, Population, Neuron, Diagnosis, Growth, Complement component 5, Geography, Brain, Prevalence, Chapter Five, Chapter Three, Pain, MedImmune, Plasma protein binding, Patient, National Multiple Sclerosis Society, Spectrum disorder, Autoimmune disease, Severe cognitive impairment, Syndrome, Awareness, CAGR, Chapter Six, Spinal cord, Protein, Type, Chugai Pharmaceutical Co., Optic nerve, NMOSD, Immune system, Paralysis, Lithium, Vaccine, Fine chemical, Pharmaceutical industry, Medical imaging, Fertilizer, Eculizumab, Devic

The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.

Key Points: 
  • The key factors responsible for growth of global Devic's syndrome treatment market are rising awareness & prevalence related to orphan diseases, recent launch of first-target specific drug Soliris (Eculizumab) and strong drug pipeline expected to provide significant growth in the market.
  • This report comprises in-depth information related to the Devic's Syndrome treatment market along with major factors affecting or assisting market such as opportunities, drivers, & restraints.
  • This report covered detailed info related to the global Devic's syndrome treatment market segmented based on drug type, and geography.
  • Global Devic's Syndrome Treatment (DST) Market: Market Dynamics and Future Outlook
    Chapter 4.

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022

Retrieved on: 
Monday, August 8, 2022 - 12:00pm
Company, Migraine, Central nervous system disease, Webcast, Research, Epilepsy, CNS, Patient, Nobel Prize, Trevena Inc, Pain, Maintenance, TRV734, Broadcasting, Pharmaceutical industry

The conference call will be webcast live from the Companys website and will be available via the following links:

Key Points: 
  • The conference call will be webcast live from the Companys website and will be available via the following links:
    The webcast should be accessed 15 minutes prior to the conference call start time.
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Companys website.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Global Neurotechnology Market Report 2022: Products will be $8.4 Billion in 2018 and will Reach $13.3 Billion in 2022 - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022 - 11:02am
Health, General Health, Carbon, Huber loss, Migraine, Parkinson's disease, Depression, Lists of diseases, Deafness, Nanotechnology, Chronic pain, Obesity, Industry, Sleep, Population, Technology, Growth, Neurorehabilitation, Market, Prevalence, Research, Pain, Quality of life, Patient, Stroke, Severe cognitive impairment, Ageing, Neurotechnology, Awareness, Epilepsy, Interface (computing), Neuroscience, MEMS, Hearing loss, Electrode, Science, Dyslexia, Autism, Physician, Hypertension, Metal, Life expectancy, Urinary incontinence, Degenerative disease, Kool-Aid, Pharmaceutical industry, Marketing, Medical device

Overall worldwide market for neurotechnology products will be $8.4 billion in 2018 and will reach $13.3 billion in 2022.

Key Points: 
  • Overall worldwide market for neurotechnology products will be $8.4 billion in 2018 and will reach $13.3 billion in 2022.
  • This newly updated market research report is the most comprehensive and up-to-date publication available covering the neurotechnology industry.
  • The report takes an in-depth look at the technology, markets, competitors, and growth rates in four key segments of the neurotechnology industry in the years 2022 through 2026.
  • The report covers in detail the key public companies and the most significant emerging and more established non-public firms in the industry.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am
Linda, FDA, Woman, Hospital, Dysmenorrhea, UCSF, Endometriosis, NYSE, Internal medicine, GLOBE, University of California, San Francisco, NEW, Senior, Norethisterone, Roivant Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pfizer, PFE, Pain, Patient, SPIRIT, Uterine fibroid, Safety, Rusyns, Webcast, Physician, University, Conditional sentence, Chair, Food, Health, Disease, Pharmaceutical industry, Dentistry, Lancet

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.